<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01734161</url>
  </required_header>
  <id_info>
    <org_study_id>1207012632</org_study_id>
    <nct_id>NCT01734161</nct_id>
  </id_info>
  <brief_title>Dexamethasone for the Prevention of Post-operative Nausea and Vomiting in Patients Undergoing Cesarean Sections</brief_title>
  <official_title>A Prospective, Randomized, Double-Blinded Study to Evaluate the Efficacy of Intravenous Dexamethasone for Nausea Prophylaxis Prior to Duramorph and Bupivacaine Spinal Anesthesia for Scheduled Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who present for scheduled (non-emergent) cesarean section will be given either&#xD;
      intravenous dexamethasone or placebo prior to receiving a duramorph containing spinal&#xD;
      anesthetic. The investigators will then compare the incidence of nausea and vomiting and the&#xD;
      use of rescue anti-nausea medications in both groups. Our hypothesis is that patients&#xD;
      receiving dexamethasone prior to duramorph containing spinal anesthesia for cesarean section&#xD;
      will have a significantly lower incidence and severity of PONV at 0, 1, 3, 6, and 24 hours&#xD;
      following surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women having cesarean sections commonly experience post-operative nausea and vomiting (PONV).&#xD;
      This can be partly attributed to the long acting morphine (duramorph) given in the anesthetic&#xD;
      (either through the epidural or in the spinal anesthetic). Intravenous dexamethasone is a&#xD;
      widely used steroid medication with a well-established safety profile which is the standard&#xD;
      of care for the prevention of PONV for general anesthesia in both adult and pediatric&#xD;
      surgical patients. Many studies have shown that when intravenous dexamethasone is&#xD;
      administered before duramorph in the epidural, the incidence of nausea and vomiting following&#xD;
      cesarean section is significantly reduced. However, when patients receive intravenous&#xD;
      dexamethasone after duramorph in a spinal anesthetic, it does not reduce the incidence of&#xD;
      nausea and vomiting. There are not any published studies where dexamethasone was administered&#xD;
      before a spinal anesthetic. The investigators believe that if dexamethasone is given&#xD;
      intravenously before duramorph in a spinal anesthetic it may reduce the incidence of nausea&#xD;
      and vomiting. Patients who present for scheduled (non-emergent) cesarean section will be&#xD;
      given either intravenous dexamethasone or placebo prior to receiving a duramorph containing&#xD;
      spinal anesthetic. The investigators will then compare the incidence of nausea and vomiting&#xD;
      and the use of rescue anti-nausea medications in both groups. Our hypothesis is that patients&#xD;
      receiving dexamethasone prior to duramorph containing spinal anesthesia for cesarean section&#xD;
      will have a significantly lower incidence and severity of PONV at 0, 1, 3, 6, and 24 hours&#xD;
      following surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Post-operative Nausea and/or Vomiting</measure>
    <time_frame>48 hours</time_frame>
    <description>The patient's self report of nausea and incidence of vomiting will be recorded intra-operatively, upon arrival to the PACU and at 1, 3, 6, 24, and 48 hours after surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One dose of 8 mg of intravenous dexamethasone diluted in 50 ml of normal saline given as an infusion over 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One dose of 50 ml of 0.9% normal saline that will be given as an infusion over 10 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>8mg IV dexamethesone given</description>
    <arm_group_label>Dexamethasone</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects randomized to placebo receive 50cc normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>50 ml 0.9% saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 18-46 presenting for scheduled primary or repeat cesarean sections and have&#xD;
             consented to study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to dexamethasone or morphine&#xD;
&#xD;
          -  history of gastrointestinal disease&#xD;
&#xD;
          -  history of severe nausea during pregnancy (hyperemesis gravidarum)&#xD;
&#xD;
          -  use of anti-emetic in the past 24 hours&#xD;
&#xD;
          -  history of gestational diabetes or diabetes mellitus&#xD;
&#xD;
          -  history of hypertension prior to or during pregnancy&#xD;
&#xD;
          -  presence of non-viable fetus&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>46 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Kjaer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/nauseaandvomiting.html</url>
    <description>Nausea and Vomiting</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0000050022&amp;QV1=DEXAMETHASONE</url>
    <description>Drug information for Dexamethasone</description>
  </link>
  <reference>
    <citation>Allen TK, Jones CA, Habib AS. Dexamethasone for the prophylaxis of postoperative nausea and vomiting associated with neuraxial morphine administration: a systematic review and meta-analysis. Anesth Analg. 2012 Apr;114(4):813-22. doi: 10.1213/ANE.0b013e318247f628. Epub 2012 Feb 17.</citation>
    <PMID>22344239</PMID>
  </reference>
  <reference>
    <citation>Cardoso MM, Leite AO, Santos EA, Gozzani JL, Mathias LA. Effect of dexamethasone on prevention of postoperative nausea, vomiting and pain after caesarean section: a randomised, placebo-controlled, double-blind trial. Eur J Anaesthesiol. 2013 Mar;30(3):102-5. doi: 10.1097/EJA.0b013e328356676b.</citation>
    <PMID>23022704</PMID>
  </reference>
  <reference>
    <citation>Hamzei A, Basiri-Moghadam M, Pasban-Noghabi S. Effect of dexamethasone on incidence of headache after spinal anesthesia in cesarean section. A single blind randomized controlled trial. Saudi Med J. 2012 Sep;33(9):948-53.</citation>
    <PMID>22964805</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 20, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2012</study_first_posted>
  <results_first_submitted>February 28, 2017</results_first_submitted>
  <results_first_submitted_qc>February 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2017</results_first_posted>
  <last_update_submitted>October 4, 2019</last_update_submitted>
  <last_update_submitted_qc>October 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cesarean section</keyword>
  <keyword>nausea</keyword>
  <keyword>vomiting</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>postoperative nausea and vomiting</keyword>
  <keyword>antiemetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share IPD</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexamethasone</title>
          <description>One dose of 8 mg of intravenous dexamethasone diluted in 50 ml of normal saline given as an infusion over 10 minutes.&#xD;
Dexamethasone: 8mg IV dexamethesone given</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>One dose of 50 ml of 0.9% normal saline that will be given as an infusion over 10 minutes.&#xD;
Placebo: Subjects randomized to placebo receive 50cc normal saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexamethasone</title>
          <description>One dose of 8 mg of intravenous dexamethasone diluted in 50 ml of normal saline given as an infusion over 10 minutes.&#xD;
Dexamethasone: 8mg IV dexamethesone given</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>One dose of 50 ml of 0.9% normal saline that will be given as an infusion over 10 minutes.&#xD;
Placebo: Subjects randomized to placebo receive 50cc normal saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="108"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.2" spread="5.2"/>
                    <measurement group_id="B2" value="35.7" spread="3.7"/>
                    <measurement group_id="B3" value="35.5" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Post-operative Nausea and/or Vomiting</title>
        <description>The patient's self report of nausea and incidence of vomiting will be recorded intra-operatively, upon arrival to the PACU and at 1, 3, 6, 24, and 48 hours after surgery</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>One dose of 8 mg of intravenous dexamethasone diluted in 50 ml of normal saline given as an infusion over 10 minutes.&#xD;
Dexamethasone: 8mg IV dexamethesone given</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One dose of 50 ml of 0.9% normal saline that will be given as an infusion over 10 minutes.&#xD;
Placebo: Subjects randomized to placebo receive 50cc normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Post-operative Nausea and/or Vomiting</title>
          <description>The patient's self report of nausea and incidence of vomiting will be recorded intra-operatively, upon arrival to the PACU and at 1, 3, 6, 24, and 48 hours after surgery</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexamethasone</title>
          <description>One dose of 8 mg of intravenous dexamethasone diluted in 50 ml of normal saline given as an infusion over 10 minutes.&#xD;
Dexamethasone: 8mg IV dexamethesone given</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>One dose of 50 ml of 0.9% normal saline that will be given as an infusion over 10 minutes.&#xD;
Placebo: Subjects randomized to placebo receive 50cc normal saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Tachycardia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>low body temperature</sub_title>
                <description>low body temperature</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>post-op shivering</sub_title>
                <description>post-op shivering</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>incision site bleeding</sub_title>
                <description>incision site bleeding</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Hypertension</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Transfusion Required</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Transfusion Required</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Klaus Kjaer, MD</name_or_title>
      <organization>Weill Cornell Medicine</organization>
      <phone>(212) 746-2953</phone>
      <email>klk9001@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01734161
org study id: 1207012632
nct id: NCT01734161
lead sponsor: 
has dmc: No
Patients who present for scheduled (non-emergent) cesarean section will be given either
      intravenous dexamethasone or placebo prior to receiving a duramorph containing spinal
      anesthetic. The investigators will then compare the incidence of nausea and vomiting and the
      use of rescue anti-nausea medications in both groups. Our hypothesis is that patients
      receiving dexamethasone prior to duramorph containing spinal anesthesia for cesarean section
      will have a significantly lower incidence and severity of PONV at 0, 1, 3, 6, and 24 hours
      following surgery.
Women having cesarean sections commonly experience post-operative nausea and vomiting (PONV).
      This can be partly attributed to the long acting morphine (duramorph) given in the anesthetic
      (either through the epidural or in the spinal anesthetic). Intravenous dexamethasone is a
      widely used steroid medication with a well-established safety profile which is the standard
      of care for the prevention of PONV for general anesthesia in both adult and pediatric
      surgical patients. Many studies have shown that when intravenous dexamethasone is
      administered before duramorph in the epidural, the incidence of nausea and vomiting following
      cesarean section is significantly reduced. However, when patients receive intravenous
      dexamethasone after duramorph in a spinal anesthetic, it does not reduce the incidence of
      nausea and vomiting. There are not any published studies where dexamethasone was administered
      before a spinal anesthetic. The investigators believe that if dexamethasone is given
      intravenously before duramorph in a spinal anesthetic it may reduce the incidence of nausea
      and vomiting. Patients who present for scheduled (non-emergent) cesarean section will be
      given either intravenous dexamethasone or placebo prior to receiving a duramorph containing
      spinal anesthetic. The investigators will then compare the incidence of nausea and vomiting
      and the use of rescue anti-nausea medications in both groups. Our hypothesis is that patients
      receiving dexamethasone prior to duramorph containing spinal anesthesia for cesarean section
      will have a significantly lower incidence and severity of PONV at 0, 1, 3, 6, and 24 hours
      following surgery.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Prevention
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Incidence of Post-operative Nausea and/or Vomiting
time frame: 48 hours
description: The patient's self report of nausea and incidence of vomiting will be recorded intra-operatively, upon arrival to the PACU and at 1, 3, 6, 24, and 48 hours after surgery
arm group label: Dexamethasone
arm group type: Active Comparator
description: One dose of 8 mg of intravenous dexamethasone diluted in 50 ml of normal saline given as an infusion over 10 minutes.
arm group label: Placebo
arm group type: Placebo Comparator
description: One dose of 50 ml of 0.9% normal saline that will be given as an infusion over 10 minutes.
intervention type: Drug
intervention name: Dexamethasone
description: 8mg IV dexamethesone given
arm group label: Dexamethasone
other name: Decadron
intervention type: Drug
intervention name: Placebo
description: Subjects randomized to placebo receive 50cc normal saline
arm group label: Placebo
other name: 50 ml 0.9% saline
criteria: 
gender: Female
minimum age: 18 Years
maximum age: 46 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Klaus Kjaer, MD
role: Principal Investigator
affiliation: Weill Medical College of Cornell University
facility: 
country: United States
url: http://www.nlm.nih.gov/medlineplus/nauseaandvomiting.html
description: Nausea and Vomiting
url: http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=0000050022&QV1=DEXAMETHASONE
description: Drug information for Dexamethasone
citation: Allen TK, Jones CA, Habib AS. Dexamethasone for the prophylaxis of postoperative nausea and vomiting associated with neuraxial morphine administration: a systematic review and meta-analysis. Anesth Analg. 2012 Apr;114(4):813-22. doi: 10.1213/ANE.0b013e318247f628. Epub 2012 Feb 17.
PMID: 22344239
citation: Cardoso MM, Leite AO, Santos EA, Gozzani JL, Mathias LA. Effect of dexamethasone on prevention of postoperative nausea, vomiting and pain after caesarean section: a randomised, placebo-controlled, double-blind trial. Eur J Anaesthesiol. 2013 Mar;30(3):102-5. doi: 10.1097/EJA.0b013e328356676b.
PMID: 23022704
citation: Hamzei A, Basiri-Moghadam M, Pasban-Noghabi S. Effect of dexamethasone on incidence of headache after spinal anesthesia in cesarean section. A single blind randomized controlled trial. Saudi Med J. 2012 Sep;33(9):948-53.
PMID: 22964805
responsible party type: Sponsor
mesh term: Nausea
mesh term: Vomiting
mesh term: Postoperative Nausea and Vomiting
mesh term: Dexamethasone
sharing ipd: No
ipd description: No plan to share IPD
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 